" /> Asciminib Hydrochloride - CISMeF





Preferred Label : Asciminib Hydrochloride;

NCIt synonyms : N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-3-yl)pyridine-3-carboxamidehydrogen Chloride (1/1);

NCIt definition : The hydrochloride salt form of asciminib, an orally bioavailable, allosteric Bcr-Abl1 tyrosine kinase inhibitor, with antineoplastic activity. Upon administration, asciminib targets and binds to the myristoyl pocket of the Bcr-Abl1 fusion protein at a location that is distinct from the ATP-binding domain, thereby inhibiting the activity of both wild-type Bcr-Abl and certain mutation forms, including the T315I mutation. This binding results in the inhibition of Bcr-Abl1-mediated proliferation and enhanced apoptosis of Philadelphia chromosome-positive (Ph ) hematological malignancies. The Bcr-Abl1 fusion protein tyrosine kinase is an abnormal enzyme produced by leukemia cells that contain the Philadelphia chromosome.;

UNII : C5U34S9XFV;

InChIKey : HGCOOPLEWPBLOY-PFEQFJNWSA-N;

CAS number : 2119669-71-3;

Drug name : Scemblix;

Molecule name : ABL001-AAA;

NCI Metathesaurus CUI : CL1405685;

Détails


Position du mot-clé dans l'(les) arborescence(s) : arborescence

Vous pouvez consulter :


Nous contacter.
28/07/2025


[Accueil] [Haut de page]

© CHU de Rouen. Toute utilisation partielle ou totale de ce document doit mentionner la source.